Search

Your search keyword '"Tang, Xuemei"' showing total 285 results
Start Over Author "Tang, Xuemei" Search Limiters Peer Reviewed
285 results on '"Tang, Xuemei"'

24. Exploration of the development path of university thinking and political education in the background of Internet

Author

Li Siqi and Tang Xuemei

Subjects
shannon’s theory, xgboost algorithm, balanced power distribution, digital platform, 97d60, Mathematics, QA1-939
Abstract

The effective development of Civic Education work in colleges and universities can promote the cultivation of high-quality talents. Starting from Internet information technology, this paper constructs a digital platform for Civic Education work, in which Shannon’s theory and balanced power allocation are used to optimize channel transmission and enhance the loading speed of Civic Education resources. The XGBoost algorithm is used to effectively cluster students’ learning behaviors as a way to help Civic Education workers understand students’ learning behaviors in Civic Education. The results show that the average response time is 0.327s, and the maximum throughput is 11849.478 bytes/sec. The prediction accuracy of the XGBoost algorithm for student learning behavior is 4.65%, 9.79%, and 21.79% higher than that of LR, RF, GBM, and Stacking classification models, respectively. 9.79%, 21.41%, and 13.5%, respectively. This shows that the university’s thinking and political education work can be developed through the direction of the digital Internet platform, which in turn provides a new research path for the reform and innovation of thinking and political education work.

Published
2024
Full Text
View/download PDF

26. Clinical Features and Treatment Outcomes of Chronic Nonbacterial Osteomyelitis in Children: A Multicenter Study in China

Author

LIU Haimei, ZHANG Tianyu, MA Le, ZHANG Zhiyong, XU Meng, ZHANG Tao, XU Hong, TANG Xuemei, YANG Sirui, YU Haiguo, SONG Hongmei, and SUN Li

Subjects
children, chronic nonbacterial osteomyelitis, clinical features, treatment outcomes, Medicine
Abstract

Objective To investigate the clinical features and treatment outcomes of chronic non-bacterial osteomyelitis (CNO) from five tertiary pediatric rheumatology services in China and provide possible treatment options for clinicians. Methods In this multicenter, retrospective study, pediatric patients diagnosed with CNO in Children's Hospital of Fudan University, Peking Union Medical College Hospital, Children's Hospital of Nanjing Medical University, Children's Hospital of Chongqing Medical University and the First Hospital of Jilin University from March 2014 to August 2022 were included. According to the treatment plan, the patients were divided into nonsteroidal anti-inflammatory drugs (NSAID) group, traditional disease modifying anti-rheumatic drugs (DMARD) group, tumor necrosis factor inhibitor (TNF-i) group, bisphosphonate group, and bisphosphonate+TNF-i group, and physician global assessment score was used to evaluate the efficacy. Results Retrospective data analysis showed that the disease was more common in boy sthan girls(31 vs. 27), and the average age at onset of symptoms was 8.5±3.4 years, the mean age of diagnosis was 9.8±3.2 years, and the Median follow-up was 10.9(5.0, 30.1) months. A total of 46 cases (79.3%) were diagnosed in the last 3 years. Bone pain and / or arthralgia was the predominant symptom in 54(93.1%) patients followed by fever in 31(53.4%) patients. Raised inflammatory markers (ESR and CRP) were present in 87.9% and 77.6% of the patients. The most frequently affected bones were lower limb bones, including 42 cases of femur and 41 cases of tibia; 3 patients had compression fractures of the vertebrae at the time of diagnosis. Bone biopsy was conducted in 33 cases, and subacute or chronic osteomyelitis manifested with inflammatory cells infiltration were detected. The remission rate was not statistically different between treatment groups (P=0.562), with the remission rate at 11 months in the bisphosphonate+TNF-i group being 60.0%, 55.6% and 33.3% in the NSAID and DMARD groups respectively; 66.7% and 52.4% in the NSAID and TNF-i groups respectively at 12 months. A total of 40 patients were followed up for ≥6 months, with the remission rate of 81.3%. Conclusions Our multicenter study describes the features and outcomes of CNO patients in China. The characteristics of CNO children from multiple centers in China were lack of specificity. Bone pain and/or arthralgia were the main clinical symptoms, accompanied by fever, normal white blood cells, and raised inflammatory markers (CRP and/or ESR). Although anti-inflammatory treatment regimens were different, the efficacy of the treatment groups was similar. Anti-inflammatory therapy is currently the first choice.

Published
2023
Full Text
View/download PDF

27. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN

Author

QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, and DU Hongqiang

Subjects
pten hamartoma tumor syndrome, gene, mutation, Medicine
Abstract

Objective To analyze the clinical phenotype and immunological characteristics of a patient with heterozygous mutation of PTEN and enrich the clinical phenotypes related to PTEN mutation. Methods A retrospective analysis of the clinical data of a patient with PTEN heterozygous mutation admitted to the Children's Hospital of Chongqing Medical University was conducted. Peripheral venous blood was extracted for medical whole-exome comprehensive detection, and the PTEN mutation was confirmed by Sanger sequencing. Flow cytometry was applied to detect the lymphocyte subsets and immunophenotype of the patient. The expression level of PTEN protein in peripheral blood mononuclear cells was detected by Western blot, and the healthy control was the patient's father. Results The patient was a boy of 1 year and 4 months, with macrocephaly (head circumference > P99), verrucous epidermal nevus, delayed psychomotor development and delayed language learning as the main manifestations. Gene sequencing revealed a de novo heterozygous mutation of PTEN c.388C > T(p.R130X). Reduced expression of PTEN protein was observed in peripheral blood mononuclear cells of the patient. For immunological characteristics, the IgA level mildly decreased(0.177 g/L), with increased counts of terminally differentiated memory CD4+ T cells, terminally differentiated memory CD8+ T cells, transitional B cells, but phosphorylation of PI3K/Akt/mTOR pathway in T cells was normal. The patient mainly manifested as PTEN hamartoma tumor syndrome related phenotype, without any classic activated phosphatidylinositol 3-kinase δ syndrome-like phenotype. Conclusions This patient has a de novo heterozygous mutation of PTEN c.388C > T(p.R130X), which has not been previously reported in China. This article could enrich clinicians' understanding of the disease and assist clinical diagnosis and treatment.

Published
2023
Full Text
View/download PDF

34. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

Author

Viola, Diego, Spindler, Alberto, Akikusa, Jonathan, Chaitow, Jeffrey, Huemer, Christian, Dehoorne, Joke, Wouters, Carine, Lauwerys, Bernard, Boulanger, Cecile, Saad Magalhães, Claudia, Terreri, Maria, Li, Caifeng, Tang, Xuemei, Feng, Qihua, Yu, Haiguo, Zhou, Zhixuan, Dolezalova, Pavla, Horvath, Rudolf, Herlin, Troels, Glerup, Mia, Quartier Dit Maire, Pierre, Kone Paut, Isabelle, Gervais, Elisabeth, Belot, Alexandre, Name, Investigator, Horneff, Gerd, Minden, Kirsten, Trauzeddel, Ralf, Foeldvari, Ivan, Lutz, Thomas, Helling-Bakki, Astrid, Grulich-Henn, Jürgen, Kümmerle-Deschner, Jasmin, Sawhney, Sujata, Kumar, Sathish, Janarthanan, Mahesh, Amarilyo, Gil, Butbul, Yonatan, Uziel, Yosef, Tirosh, Irit, Harel, Liora, Caorsi, Roberta, Pastore, Serena, Tommasini, Alberto, Alessio, Maria, Breda, Luciana, Cattalini, Marco, Cimaz, Rolando, Giani, Teresa, Simonini, Gabriele, Filocamo, Giovanni, Umebayashi, Hiroaki, Kaneko, Utako, Kawano, Yutaka, Sato, Satoshi, Mori, Masaaki, Shimizu, Masaki, Yamaguchi, Kenichi, Ito, Shuichi, Imagawa, Tomoyuki, Inoue, Natsumi, Yokoyama, Tadafumi, Shabana, Kosuke, Ozeki, Yuka, Kawano, Yoshifumi, Yamasaki, Yuichi, Miyamae, Takako, Vega Cornejo, Gabriel, Rubio Perez, Nadina, Vargas, Edgar, Pacheco-Tena, Cesar, Edmundo Enriquez Sosa, Favio, Smolewska, Elzbieta, Zuber, Zbigniew, Gietka, Piotr, Alexeeva, Ekaterina, Nikishina, Irina, Valieva, Sania, Antón López, Jordi, Murias Loza, Sara, Maria Alcobendas Rueda, Rosa, Calvo Penades, Inmaculada, Grana, Genaro, Lucica Boteanu, Alina, Kasapcopur, Ozgur, Unsal, Erbil, Vaidyanathan Ramanan, Athimalaipet, Lacassagne, Sandrine, Hawley, Daniel, Mahmood, Kamran, Almeida, Beverley, Ramanan, Athimalaipet V, Quartier, Pierre, Okamoto, Nami, Fingerhutová, Šárka, Antón, Jordi, Wang, Zhongkai, Meszaros, Gabriella, Araújo, Joana, Liao, Ran, Keller, Stuart, Brunner, Hermine I, and Ruperto, Nicolino

Published
2023
Full Text
View/download PDF

40. Time series analysis revealed prognostic value of continuous nasopharyngeal SARS-CoV-2 nucleic acid quantification for COVID-19: A retrospective study of >3000 COVID-19 patients from 2 centers

Author

Wu, Zhiyuan, Yang, Can, Shen, Yutao, Zhang, Qingyun, Tang, Xuemei, Wang, Di, Xu, Yu, Cao, Guojun, Song, Xiaodong, Ma, Yanchun, Fan, Huajie, Lu, Hailong, Li, Yaju, Li, Xiangyu, Shen, Yiqin, Zhang, Chen, Zhu, Min, Teng, Xiaoyan, Du, Yuzhen, and Guan, Ming

Published
2023
Full Text
View/download PDF

45. Clinical Characteristics and Treatment of Blau Syndrome in Chinese Children-a National Multicenter Study

Author

ZHANG Junmei, ZHAO Xiaozhen, TANG Xuemei, ZHAO Yi'nan, LI Li, GAO Fengqiao, SHI Xinwei, JIN Yanliang, ZHANG Yu, CAO Lanfang, YIN Wei, XIAO Jihong, KUANG Weiying, DENG Jianghong, WANG Jiang, TAN Xiaohua, LI Chao, LI Shipeng, XUE Haiyan, LIU Cuihua, LIU Xiaohui, ZHAO Dongmei, CHEN Yuqing, ZHENG Wenjie, and LI Caifeng

Subjects
blau syndrome, demographic characteristics, clinical manifestations, treatment, Medicine
Abstract

Objective To study the demographic and clinical characteristics, correlation of genotype and phenotype and treatment of Blau syndrome to facilitate early diagnosis and timely treatment of Blau syndrome. Methods Seventy-two patients with Blau syndrome from 11 centers from May 2006 to April 2022 were retrospectively analyzed, and their general information, clinical data, laboratory examination and treatment medication were collected. Results The distribution of patients with Blau syndrome was uniform in geographical north and south of China, and there was no obvious gender bias. The mean age of onset was (14.30±12.81) months, and the age of diagnosis was (55.18±36.22) months. 35% of patients with Blau syndrome happened before 1 year old, and all patients developed before 5 years old. 87.50% (63/72) had granulomatous arthritis, 65.28% (47/72) had rash, 36.11% (26/72) had ocular involvement, 27.78% (20/72) had fever, and 15.28% (11/72) had pulmonary involvement. Arthritic manifestations of Blau syndrome were most at risk, followed by rash, ocular involvement, and fever.The first 25 months of the disease, the risk of developing a rash was the greatest. The risk of developing arthritis was the greatest between 25 months and 84 months. The main mutations were p.R334Q and p.R334W, and patients with p.R334Q mutation had relatively high incidence of fever (35.71%[5/14] vs. 14.29%[1/7], P=0.43) and ocular involvement (42.86%[6/14]vs. 28.57%[2/7], P=0.51). There was a relatively high incidence of rash (85.71%[6/7] vs. 64.29%[9/14], P=0.59) in patients with the p.R334W mutation. Forty-five patients(62.50%)were treated with a combina-tion of glucocorticoid and methotrexate. Twenty-two patients were treated with tumor necrosis factor antagonist in addition to glucocorticoid and methotrexate. Conclusions The risk of different clinical manifestations of Blau syndrome from high to low was arthritis, followed by rash, ocular involvement and fever. The main treatment was glucocorticoid combined with methotrexate, to which biological agents could be added.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results